Patients with Crohn's disease who are considered high-risk as determined by capsule endoscopy but are in clinical remission benefit from a treat-to-target strategy, a new study shows.
A groundbreaking study conducted at Sheba Medical Center in Tel Hashomer has revealed that machine-learning analysis of complete capsule endoscopy (CE) | BLiTZ
Research by Israel's Sheba Medical Center and Intel found machine-learning analysis of complete capsule endoscopy to help predict the need for biological therapy to treat Crohn's disease.
Professor at Israel s Sheba hospital says predicting disease progression and outcomes is a critical challenge, as he remarks on impact of machine learning - Click the link for more details.